A comprehensive view of Sanofi SA. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Sanofi to conduct Phase 3 clinical trial to evaluate subcutaneous vs intravenous administration of Isatuximab with Pomalidomide and Dexamethasone in adults with relapsed or refractory multiple myeloma; recruitment has not yet started

FDA grants breakthrough therapy designation to Sanofi’s efanesoctocog alfa BIVV001 injectable to treat hemophilia A, a life-threatening bleeding disorder; hemophilia A is a lifelong condition that affects about one in 5,000 males, fewer females

Sanofi reports Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron BA.1, BA.2; company states booster has stronger immune response than Pfizer-BioNTech’s Comirnaty booster

Regeneron and Sanofi’s injectable anti-inflammatory drug Dupixent dupilumab cleared in US to treat children six months to five years old with atopic dermatitis or eczema; drug had previously been approved for children aged six years and older

Alpine Immune Sciences appoints Andrew S. Sandler, M.D. as chief medical officer to assist in advancement of three oncology, autoimmune disease indication development programs; Dr. Sandler previously served as chief medical officer at Kiadis Pharma

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count